PMID- 12406663
OWN - NLM
STAT- MEDLINE
DCOM- 20030221
LR  - 20151119
IS  - 1094-5539 (Print)
IS  - 1094-5539 (Linking)
VI  - 15
IP  - 5
DP  - 2002
TI  - Anti-immunoglobulin E therapy for asthma.
PG  - 417-24
AB  - The role of immunoglobulin E (IgE) in allergic asthmatic disease is well 
      established. Allergen-specific IgE binds to its cognate receptors, thus 
      triggering a series of cellular events. These events include presentation of 
      antigen by dendritic cells and the degranulation of mast cells and basophils to 
      release numerous factors that play an integral part in potentiating the disease 
      symptoms. Studies in the mouse indicate that a reduction in IgE levels could lead 
      to significant attenuation of the allergic inflammatory response associated with 
      diseases such as asthma, making IgE a target for the development of new 
      therapeutic agents. Omalizumab (Xolair, a recombinant humanized monoclonal 
      anti-IgE antibody that blocks the interaction of IgE with its receptors, is the 
      first anti-IgE agent to undergo clinical development. Several clinical studies 
      have been performed in adults and children with moderate-to-severe allergic 
      asthma to evaluate the efficacy and safety of this agent. Treatment with 
      omalizumab was well tolerated and showed clinical benefit in terms of a reduction 
      in the frequency and number of asthma exacerbation episodes and lower usage of 
      corticosteroids and other medications to control disease, along with improved 
      quality of life. Such findings indicate that omalizumab represents a promising 
      new treatment option for allergic asthma.
FAU - Owen, Charles E
AU  - Owen CE
AD  - Novartis Horsham Research Centre, Horsham, UK
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Pulm Pharmacol Ther
JT  - Pulmonary pharmacology & therapeutics
JID - 9715279
RN  - 0 (Antibodies, Anti-Idiotypic)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 2P471X1Z11 (Omalizumab)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Animals
MH  - Antibodies, Anti-Idiotypic
MH  - Antibodies, Monoclonal/pharmacokinetics/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Asthma/*drug therapy/immunology
MH  - Clinical Trials, Phase II as Topic
MH  - Clinical Trials, Phase III as Topic
MH  - Humans
MH  - Hypersensitivity/drug therapy/immunology
MH  - Immunoglobulin E/*immunology/metabolism
MH  - Models, Animal
MH  - Omalizumab
MH  - Quality of Life
RF  - 51
EDAT- 2002/10/31 04:00
MHDA- 2003/02/22 04:00
CRDT- 2002/10/31 04:00
PHST- 2002/10/31 04:00 [pubmed]
PHST- 2003/02/22 04:00 [medline]
PHST- 2002/10/31 04:00 [entrez]
AID - S1094-5539(02)90372-X [pii]
AID - 10.1006/pupt.2002.0372 [doi]
PST - ppublish
SO  - Pulm Pharmacol Ther. 2002;15(5):417-24. doi: 10.1006/pupt.2002.0372.